Wereld Diabetes Dag, 14 november 2020

PARIJS & WALTHAM, Mass. – (BUSINESS WIRE) – Echosens, een hoogtechnologisch bedrijf dat de FibroScan-productfamilie aanbiedt, erkent het belang van Wereld Diabetes Dag (WDD), 14 november, ondersteunt de International Diabetes Federation en de World Health Organization, en voegt zich bij leiders in de gezondheidszorg over de hele wereld om het bewustzijn te vergroten over non-alcoholic fatty liver disease (NAFLD) en de prevalentie van 70% onder type 2-diabetespatiënten. Het begrijpen van de levergezondheid bij mensen met type 2-diabetes is van toenemend belang, aangezien gegevens suggereren dat mensen met type 2-diabetes en NAFLD een tweevoudig risico lopen op sterfte door alle oorzaken dan degenen die alleen met type 2-diabetes leven.

Echosens Highlights Link Between Diabetes and Liver Disease, Urges Non-Invasive Detection and Monitoring of Liver Fat to Halt Disease Progression

World Diabetes Day, November 14, 2020

PARIS & WALTHAM, Mass.–(BUSINESS WIRE)– Echosens, a high-technology company offering the FibroScan family of products, recognizes the importance of World Diabetes Day (WDD), Nov. 14, supports the International Diabetes Federation and the World Health Organization, and joins healthcare leaders worldwide to raise awareness about non-alcoholic fatty liver disease (NAFLD) and its 70% prevalence among Type 2 diabetes patients. Understanding liver health in people living with Type 2 diabetes is of growing importance as data suggest that people living with Type 2 diabetes and NAFLD are at a two-fold risk of all-cause mortality versus those living with Type 2 diabetes alone.

“World Diabetes Day, the world’s largest diabetes awareness campaign reaching a global audience of over one billion people in more than 160 countries, is an opportunity to emphasize how NAFLD may contribute to prediabetes and Type 2 diabetes,” Dominique Legros, Echosens Group CEO, noting that approximately 463 million adults live with diabetes and by 2045 that number will rise to 700 million. “Fat in the liver can increase the risks of progression of prediabetes to overt disease. Once a patient has fatty liver disease, diabetes may become more difficult to control, making it critical to obtain an early diagnosis and introduce lifestyle changes to halt or reverse NAFLD.”

FibroScan, a painless, non-invasive exam at the point of care can measure and monitor the amount of liver stiffness and detect NAFLD in its earliest stages when the individual may be asymptomatic. It can be used to rule out the need for further assessment, such as a painful liver biopsy, saving time and resources for people who don’t need further assessment.

“Even moderate weight loss can significantly reduce liver fat in patients with NAFLD and play an essential role in the prevention and treatment of Type 2 diabetes,” adds Dominique Legros. “WDD is an excellent time to begin promoting advocacy efforts throughout the year and confront diabetes as a critical global health issue.”

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is recognized worldwide as the reference for non-invasive liver fibrosis and liver steatosis assessment with more than 2,500+ peer reviewed publications and 60+ international guidelines recommendations. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201114005002/en/

Contacts

Media:
Brittany Tedesco

CPR Communications

btedesco@cpronline.com
201.641.1911 x 14

Claire Mario

claire.mario@echosens.com
+33(0)1-44-82-78-50